A Review on Modern Use of Intranasal Vaccination in the Treatment of SARS-COV-2

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for efficient SARS 2 (SARS-CoV-2) preventative vaccines to limit burden and spread of SARS-CoV-2 in humans. Intranasal immunization is a promising technique preventing COVID-19 because nasal mucosa acts as first line defense against entrance before virus spreads lungs. Nasal vaccination many advantages over traditional vaccine administration methods. These include simplicity without use needles, which decreases risks needle stick injuries disposal. This channel also provides simple access crucial portion immune system that can stimulate other mucosal sites throughout body. By targeting immunoglobulin A (IgA), antibodies found only mucosa, an intranasal would elicit immunological responses nose, throat, Potential pathogens are trapped by physical barrier prevent them from entering Given this, transmission via exhaled droplets or aerosols there be no body expel .There several protection sars-cov2 under preclinical clinical trials .The key challenge Designing delivery strategies take into account wide range diseases, populations, healthcare settings stand benefit this unique route should prioritized.
 Keywords: COVID-19, vaccine, Immunoglobulin A, Permeation